AgingResearch.NewsJoin free

PNR886

Intervention

1 paper studies it3 findings

Across all fields, 1 paper: none in people yet, 1 in animals

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: National Institute on Aging and 3 more
  • Model organisms1

Outcomes

3

Healthspan

upin worms1+29%

1 study

  1. PNR886 improves healthspan in worms (+29%).

    “healthspan" (the median duration of spontaneous motility) was extended 29% and 62%, respectively.”

    Model organismsexpressing human Aβ1-42 in muscle

    Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan

    Pharmaceuticals (Basel, Switzerland)

Paralysis

downin worms1−90%

1 study

  1. PNR886 decreases paralysis in worms (-90%).

    “age-progressive paralysis was reduced 90% by PNR886 and 75% by PNR962”

    Model organismsexpressing human Aβ1-42 in musclemuscle

    Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan

    Pharmaceuticals (Basel, Switzerland)

Protein aggregates

downin human cells1

1 study

  1. PNR886 decreases protein aggregates in human cells.

    “PNR886 and PNR962 were most effective, significantly reducing both the number and intensity of Alzheimer-like tau and amyloid aggregates in human cell-culture models of pathogenic aggregation.”

    Cellsin human cell-culture models of pathogenic aggregation

    Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan

    Pharmaceuticals (Basel, Switzerland)

Latest

Related